Results from this prospective, open-label, phase Ib study show that the combination of metformin and chloroquine has a favorable toxicity profile but no clinical activity in patients with IDH1-mutated chondrosarcoma, glioma and intrahepatic cholangiocarcinoma. Here, IDH1 is linked to central nervous system cancer.